Eli Lilly & Co. has seen a share price increase of over 40.4%, significantly outperforming the Zacks Large Cap Pharmaceuticals industry, driven by heightened demand for drugs like Trulicity and Taltz. The company's exciting drug pipeline, including tirzepatide and donanemab, is projected to yield multibillion-dollar sales, while Q1 revenue hit $7.81 billion with a 15% growth year-over-year. Additionally, Eli Lilly secured a $275 million deal with the U.S. government for COVID-19 treatment doses, even as a restructuring threatens around 1,400 jobs in Switzerland.
“Eli Lilly shares · have outperformed · the Zacks Large Cap Pharmaceuticals industry · +40.4% vs. +19.8%”
“Eli Lilly · has a pipeline of potential new medicines · tirzepatide and donanemab · multibillion dollar sales potential”
“Eli Lilly · has outperformed · Zacks Large Cap Pharmaceuticals industry · +40.4% vs. +19.8%”
“Eli Lilly · is driven by · higher demand for drugs · like Trulicity, Taltz, and others”
“Eli Lilly · has an exciting pipeline of · potential new medicines · including tirzepatide and donanemab”
“Eli Lilly shares · have outperformed · Zacks Large Cap Pharmaceuticals industry · +40.4% vs. +19.8%”
“Eli Lilly shares · outperformed · Zacks Large Cap Pharmaceuticals industry · +40.4% vs. +19.8%”
“Eli Lilly (LLY) · has · shares · up 17% this year”
“Eli Lilly · shares · performance · up more than 18% since the end of 2021”
“Eli Lilly · COVID-19 treatment · bamlanivimab and etesevimab · credit goes to”
“Eli Lilly · diabetes treatment · Trulicity · heavy hitter”
“Eli Lilly (LLY) · is · year-to-date gains · 17%”
%20-%20USA%20-%20UNOCHA.svg&width=160)